LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between MEI PHARMA, INC., and KYOWA KIRIN CO., LTD. EFFECTIVE DATE: APRIL 10, 2020Development and Commercialization Agreement • September 9th, 2020 • MEI Pharma, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 9th, 2020 Company Industry JurisdictionThis License, Development and Commercialization Agreement (this “Agreement”), dated as of April 10, 2020 (the “Effective Date”), is made by and between MEI Pharma, Inc., a Delaware corporation having an office at 3611 Valley Centre Drive STE 500, San Diego, CA 92130 (“MEI”), and Kyowa Kirin Co., Ltd. (formerly known as Kyowa Hakko Kirin Co., Ltd.), a Japanese corporation having an office at 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan (“KKC”). MEI and KKC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.